Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 7,700 shares at $17.06 ($131K) on 2019-12-16, disclosed to the SEC on 2019-12-16.
Open-market sale of $131k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.00 | 100 | $2K | 1.3% |
| 2 | $17.06 | 2,200 | $38K | 28.6% |
| 3 | $17.06 | 5,400 | $92K | 70.1% |
| Total | $17.06 avg | 7,700 | $131K | 100% |
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |